Suppr超能文献

极光激酶A与N-Myc结合的结构基础及其被激酶抑制剂破坏的机制

Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.

作者信息

Richards Mark W, Burgess Selena G, Poon Evon, Carstensen Anne, Eilers Martin, Chesler Louis, Bayliss Richard

机构信息

Astbury Centre for Structural and Molecular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, United Kingdom.

Cancer Research UK Leeds Centre, University of Leeds, Leeds LS2 9JT, United Kingdom.

出版信息

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13726-13731. doi: 10.1073/pnas.1610626113. Epub 2016 Nov 11.

Abstract

Myc family proteins promote cancer by inducing widespread changes in gene expression. Their rapid turnover by the ubiquitin-proteasome pathway is regulated through phosphorylation of Myc Box I and ubiquitination by the E3 ubiquitin ligase SCF However, N-Myc protein (the product of the MYCN oncogene) is stabilized in neuroblastoma by the protein kinase Aurora-A in a manner that is sensitive to certain Aurora-A-selective inhibitors. Here we identify a direct interaction between the catalytic domain of Aurora-A and a site flanking Myc Box I that also binds SCF We determined the crystal structure of the complex between Aurora-A and this region of N-Myc to 1.72-Å resolution. The structure indicates that the conformation of Aurora-A induced by compounds such as alisertib and CD532 is not compatible with the binding of N-Myc, explaining the activity of these compounds in neuroblastoma cells and providing a rational basis for the design of cancer therapeutics optimized for destabilization of the complex. We also propose a model for the stabilization mechanism in which binding to Aurora-A alters how N-Myc interacts with SCF to disfavor the generation of Lys48-linked polyubiquitin chains.

摘要

Myc家族蛋白通过诱导基因表达的广泛变化来促进癌症发生。它们通过泛素-蛋白酶体途径的快速周转是由Myc Box I的磷酸化以及E3泛素连接酶SCF的泛素化作用来调控的。然而,在神经母细胞瘤中,N-Myc蛋白(MYCN癌基因的产物)通过蛋白激酶Aurora-A得以稳定,这种稳定方式对某些Aurora-A选择性抑制剂敏感。在此,我们鉴定出Aurora-A的催化结构域与Myc Box I侧翼的一个位点之间存在直接相互作用,该位点也能结合SCF。我们确定了Aurora-A与N-Myc这一区域复合物的晶体结构,分辨率达到1.72 Å。该结构表明,alisertib和CD532等化合物诱导的Aurora-A构象与N-Myc的结合不相容,这解释了这些化合物在神经母细胞瘤细胞中的活性,并为设计针对复合物去稳定化优化的癌症治疗药物提供了合理依据。我们还提出了一种稳定机制模型,其中与Aurora-A的结合改变了N-Myc与SCF相互作用的方式,不利于生成赖氨酸48连接的多聚泛素链。

相似文献

1
Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors.
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13726-13731. doi: 10.1073/pnas.1610626113. Epub 2016 Nov 11.
2
A moving target: structure and disorder in pursuit of Myc inhibitors.
Biochem Soc Trans. 2017 Jun 15;45(3):709-717. doi: 10.1042/BST20160328.
3
PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc.
Int J Mol Sci. 2021 Dec 4;22(23):13122. doi: 10.3390/ijms222313122.
4
Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.
Cancer Cell. 2013 Jul 8;24(1):75-89. doi: 10.1016/j.ccr.2013.05.005. Epub 2013 Jun 20.
5
Drugging MYCN through an allosteric transition in Aurora kinase A.
Cancer Cell. 2014 Sep 8;26(3):414-427. doi: 10.1016/j.ccr.2014.07.015. Epub 2014 Aug 28.
6
Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.
Cancer Cell. 2009 Jan 6;15(1):67-78. doi: 10.1016/j.ccr.2008.12.005.
7
Aurora kinases as targets in drug-resistant neuroblastoma cells.
PLoS One. 2014 Sep 30;9(9):e108758. doi: 10.1371/journal.pone.0108758. eCollection 2014.
9
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Nat Med. 2016 Jul;22(7):744-53. doi: 10.1038/nm.4107. Epub 2016 May 23.

引用本文的文献

1
Development of Dual Aurora-A and Aurora-B Degrading PROTACs for -Amplified Neuroblastoma.
ChemMedChem. 2025 Mar 3;20(5). doi: 10.1002/cmdc.202400703. Epub 2024 Nov 20.
2
Disruption of the KLHL37-N-Myc complex restores N-Myc degradation and arrests neuroblastoma growth in mouse models.
J Clin Invest. 2025 Jun 10;135(14). doi: 10.1172/JCI176655. eCollection 2025 Jul 15.
3
MYC: The Guardian of Its Own Chaos.
Bioessays. 2025 Jul;47(7):e70010. doi: 10.1002/bies.70010. Epub 2025 Jun 9.
4
Inhibition of Dormant Lung Cancer Cell Reactivation by and : Involving MYC, SKP2 and p27.
Drug Des Devel Ther. 2025 May 15;19:3997-4010. doi: 10.2147/DDDT.S494168. eCollection 2025.
6
MYCN as an oncogene in pediatric brain tumors.
Front Oncol. 2025 Apr 29;15:1584978. doi: 10.3389/fonc.2025.1584978. eCollection 2025.
7
Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology.
Genes Dis. 2024 Sep 16;12(4):101435. doi: 10.1016/j.gendis.2024.101435. eCollection 2025 Jul.
9
Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma.
Front Oncol. 2025 Mar 4;15:1553511. doi: 10.3389/fonc.2025.1553511. eCollection 2025.
10
Resistance to FLT3 inhibitors involves different molecular mechanisms and reduces new DNA synthesis.
Biochem Biophys Rep. 2025 Jan 16;41:101894. doi: 10.1016/j.bbrep.2024.101894. eCollection 2025 Mar.

本文引用的文献

1
Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain.
Open Biol. 2016 Jul;6(7). doi: 10.1098/rsob.160089.
3
Ubiquitin-Dependent Turnover of MYC Antagonizes MYC/PAF1C Complex Accumulation to Drive Transcriptional Elongation.
Mol Cell. 2016 Jan 7;61(1):54-67. doi: 10.1016/j.molcel.2015.11.007. Epub 2015 Dec 10.
4
Pre-Anchoring of Pin1 to Unphosphorylated c-Myc in a Fuzzy Complex Regulates c-Myc Activity.
Structure. 2015 Dec 1;23(12):2267-2279. doi: 10.1016/j.str.2015.10.010. Epub 2015 Nov 19.
5
MYC: connecting selective transcriptional control to global RNA production.
Nat Rev Cancer. 2015 Oct;15(10):593-607. doi: 10.1038/nrc3984. Epub 2015 Sep 18.
6
Aurora-A-Dependent Control of TACC3 Influences the Rate of Mitotic Spindle Assembly.
PLoS Genet. 2015 Jul 2;11(7):e1005345. doi: 10.1371/journal.pgen.1005345. eCollection 2015 Jul.
7
The structure of C290A:C393A Aurora A provides structural insights into kinase regulation.
Acta Crystallogr F Struct Biol Commun. 2015 Mar;71(Pt 3):315-9. doi: 10.1107/S2053230X15002290. Epub 2015 Feb 19.
8
Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.
Cancer Cell. 2015 Jan 12;27(1):72-84. doi: 10.1016/j.ccell.2014.11.002. Epub 2014 Dec 18.
9
Taming of the beast: shaping Myc-dependent amplification.
Trends Cell Biol. 2015 Apr;25(4):241-8. doi: 10.1016/j.tcb.2014.10.006. Epub 2014 Dec 1.
10
Drugging MYCN through an allosteric transition in Aurora kinase A.
Cancer Cell. 2014 Sep 8;26(3):414-427. doi: 10.1016/j.ccr.2014.07.015. Epub 2014 Aug 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验